RDY
Dr. Reddy's Laboratories Limited
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
12.18
▲ 0.07 (0.58%)
MARKET · —
Price
Open
12.11
Prev close
12.11
Day high
12.22
Day low
12.07
Volume
1.75M
Market cap
$10.15B
P/E (TTM)
29.00
52W range
11.36 – 15.67
Trailing performance
Returnvs SPY
1W
-0.73%
+0.6%
1M
+3.22%
-0.5%
3M
-10.11%
-13.2%
6M
-15.94%
-27.0%
YTD
-13.25%
-25.5%
1Y
-13.80%
-33.8%
3Y
-14.23%
-88.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$10.15B
Enterprise value$54.58B
Revenue (TTM)$331.19B
Gross profit$166.18B
EBITDA$54.67B
Net income$33.11B
EPS (TTM)$0.42
Free cash flow$-3.91B
Total cash$81.43B
Total debt$71.95B
Book value / share$0.80
Shares outstanding833.00M
Float3.59B
Short % of float3.05%
Dividend yield0.68%
Beta (5Y)0.24
Valuation & profitability ratios
Trailing P/E29.00
Forward P/E18.79
PEG ratio1.61
Price / sales—
Price / book15.13
EV / revenue0.17
EV / EBITDA1.00
Gross margin50.18%
Operating margin4.25%
Profit margin10.00%
Return on equity8.84%
Return on assets4.01%
Debt / equity18.61
Current ratio1.90
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $335.93B | $325.54B | $279.16B | $246.70B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $42.85B | $56.54B | $55.78B | $45.07B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | $42.85B | $56.54B | $55.78B | $45.07B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $84.51B | -4.0% |
| Next quarter | — | — | $89.85B | +3.0% |
| Current year | 43.85 | 1 | $351.91B | +4.8% |
| Next year | 62.08 | 1 | $392.78B | +11.6% |
Analyst targets & ownership
Mean target$13.44
High target$15.73
Low target$11.36
Implied upside10.34%
Analyst count5
ConsensusHOLD
Strong buy / Buy0 / 2
Hold2
Sell / Strong sell1 / 0
Held by insiders0.00%
Held by institutions15.90%
Institutions holding332
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Moving averages & technicals
SMA 10
12.23
-0.44% from price
SMA 20
12.10
+0.69% from price
SMA 50
12.94
-5.87% from price
SMA 100
13.15
-7.35% from price
SMA 200
13.54
-10.03% from price
EMA 12
12.18
-0.04% from price
EMA 26
12.34
-1.33% from price
EMA 50
12.66
-3.83% from price
RSI (14)
44.4
Neutral
MACD (12,26,9)
-0.16
Hist 0.06
ATR (14)
0.22
1.85% of price
Realised vol 30D
33.0%
Annualised
Bollinger upper
12.51
20, 2σ
Bollinger lower
11.68
20, 2σ
50 / 200 cross
Death
12.94 vs 13.54
Trend bias
Below 200
-10.03%
Risk profile
Beta vs SPY
0.21
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
33.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-26.0%
Peak to trough
Max drawdown 5Y
-32.4%
Peak to trough
ATR 14
0.22
1.85% of price
Beta (reported)
0.24
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
4.31
Put-heavy session
Put / call open interest
0.39
Positioning, not flow
Max pain
10.00
-17.9% from spot
ATM implied vol
43.8%
Nearest strike to spot
Skew (10% OTM)
+19.5%
Puts bid over calls
Call volume
26
Contracts, this expiry
Put volume
112
Contracts, this expiry
Heaviest call OI
10.00
185 contracts
Heaviest put OI
12.50
129 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
MT Newswires · 4d ago
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
MT Newswires · 8d ago
Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
MT Newswires · 9d ago
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
MT Newswires · 10d ago
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
MT Newswires · 11d ago
Asian Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
MT Newswires · 12d ago
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires · 16d ago
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
Business Wire · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.